Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

16.43 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neogenomics Inc

< Previous 1 2 3 4 5 6 7 Next >
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Reports Third Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Reports Third Quarter 2023 Results
Via ACCESSWIRE
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Reports Second Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
From NeoGenomics, Inc.
Via Business Wire
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Reports First Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Announces Senior Leadership Promotions
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
From NeoGenomics, Inc.
Via Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO
From The Rosen Law Firm, P.A.
Via Business Wire
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
NeoGenomics to Appeal Ruling
Via ACCESSWIRE
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
Via ACCESSWIRE
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
Via ACCESSWIRE
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.